MARC details
000 -LEADER |
fixed length control field |
04546nam a22006737a 4500 |
008 - FIXED-LENGTH DATA ELEMENTS--GENERAL INFORMATION |
fixed length control field |
130913s20122012 xxu||||| |||| 00| 0 eng dOvid Technologies |
022 ## - INTERNATIONAL STANDARD SERIAL NUMBER |
International Standard Serial Number |
0002-9149 |
040 ## - CATALOGING SOURCE |
Original cataloging agency |
Ovid MEDLINE(R) |
099 ## - LOCAL FREE-TEXT CALL NUMBER (OCLC) |
PMID |
22341925 |
245 ## - TITLE STATEMENT |
Title |
Safety and efficacy of the XIENCE V everolimus-eluting stent compared to first-generation drug-eluting stents in contemporary clinical practice. |
251 ## - Source |
Source |
American Journal of Cardiology. 109(9):1288-94, 2012 May 1. |
252 ## - Abbreviated Source |
Abbreviated source |
Am J Cardiol. 109(9):1288-94, 2012 May 1. |
253 ## - Journal Name |
Journal name |
The American journal of cardiology |
260 ## - PUBLICATION, DISTRIBUTION, ETC. |
Year |
2012 |
260 ## - PUBLICATION, DISTRIBUTION, ETC. |
Manufacturer |
FY2012 |
266 ## - Date added to catalog |
Date added to catalog |
2013-09-17 |
501 ## - WITH NOTE |
Local holdings |
Available online from MWHC library: 1995 - present, Available in print through MWHC library: 1999 - 2006 |
520 ## - SUMMARY, ETC. |
Abstract |
Data from randomized clinical trials have shown the safety and efficacy of the XIENCE V in selected populations. However, limited data are available comparing the XIENCE V to the first-generation CYPHER sirolimus-eluting stent. This study aimed to assess the long-term safety and clinical efficacy of the XIENCE V everolimus-eluting stent compared to first-generation stents in an unselected patient population. This retrospective analysis included 6,069 patients treated with CYPHER, TAXUS, and XIENCE stents from 2003 to 2009 at our institution. The patients were followed up for >=1 year after the index procedure. The baseline characteristics were generally comparable among the 3 groups, with the exception of a significantly greater prevalence of diabetes mellitus, systemic hypertension, and a history of angioplasty and coronary bypass surgery among the XIENCE patients. The XIENCE patients also had a twofold greater rate of type C lesions. One-year follow-up data were available for 82% of the patients. The 1-year major adverse cardiovascular events rate was 9.3% for the XIENCE stent versus 9.8% for the CYPHER stent and 11.5% for the TAXUS stent (p = 0.11). Mortality was lower in the XIENCE group than in the CYPHER and TAXUS groups (3.6% vs 4.9% vs 7.2%, respectively, p <0.001), and target lesion revascularization was similar (5.9% vs 5.2% vs 5.6%, respectively; p = 0.34). Stent thrombosis was lower in the XIENCE patients (0.2% vs 1.2% vs 0.7%, p = 0.007). In conclusion, in a contemporary United States clinical practice with an unselected patient population, use of the XIENCE V stent was associated with an improved safety profile and reduction of all-cause mortality and stent thrombosis compared to first-generation drug-eluting stents. The XIENCE V failed to demonstrate superiority for overall major adverse cardiovascular events, Q-wave myocardial infarction, and revascularization rates. Copyright 2012 Elsevier Inc. All rights reserved. |
546 ## - LANGUAGE NOTE |
Language note |
English |
650 ## - SUBJECT ADDED ENTRY--TOPICAL TERM |
Topical term or geographic name entry element |
*Angioplasty, Balloon, Coronary/mt [Methods] |
9 (RLIN) |
952 |
650 ## - SUBJECT ADDED ENTRY--TOPICAL TERM |
Topical term or geographic name entry element |
*Coronary Artery Disease/th [Therapy] |
9 (RLIN) |
171 |
650 ## - SUBJECT ADDED ENTRY--TOPICAL TERM |
Topical term or geographic name entry element |
*Drug-Eluting Stents |
9 (RLIN) |
525 |
650 ## - SUBJECT ADDED ENTRY--TOPICAL TERM |
Topical term or geographic name entry element |
*Sirolimus/aa [Analogs & Derivatives] |
9 (RLIN) |
674 |
650 ## - SUBJECT ADDED ENTRY--TOPICAL TERM |
Topical term or geographic name entry element |
Aged |
9 (RLIN) |
2 |
650 ## - SUBJECT ADDED ENTRY--TOPICAL TERM |
Topical term or geographic name entry element |
Antineoplastic Agents, Phytogenic/pd [Pharmacology] |
9 (RLIN) |
966 |
650 ## - SUBJECT ADDED ENTRY--TOPICAL TERM |
Topical term or geographic name entry element |
Coronary Angiography |
9 (RLIN) |
90 |
650 ## - SUBJECT ADDED ENTRY--TOPICAL TERM |
Topical term or geographic name entry element |
Coronary Artery Disease/ra [Radiography] |
9 (RLIN) |
91 |
650 ## - SUBJECT ADDED ENTRY--TOPICAL TERM |
Topical term or geographic name entry element |
Coronary Restenosis/pc [Prevention & Control] |
9 (RLIN) |
967 |
650 ## - SUBJECT ADDED ENTRY--TOPICAL TERM |
Topical term or geographic name entry element |
Female |
9 (RLIN) |
7 |
650 ## - SUBJECT ADDED ENTRY--TOPICAL TERM |
Topical term or geographic name entry element |
Follow-Up Studies |
9 (RLIN) |
968 |
650 ## - SUBJECT ADDED ENTRY--TOPICAL TERM |
Topical term or geographic name entry element |
Humans |
9 (RLIN) |
11 |
650 ## - SUBJECT ADDED ENTRY--TOPICAL TERM |
Topical term or geographic name entry element |
Immunosuppressive Agents/pd [Pharmacology] |
9 (RLIN) |
969 |
650 ## - SUBJECT ADDED ENTRY--TOPICAL TERM |
Topical term or geographic name entry element |
Male |
9 (RLIN) |
14 |
650 ## - SUBJECT ADDED ENTRY--TOPICAL TERM |
Topical term or geographic name entry element |
Middle Aged |
9 (RLIN) |
15 |
650 ## - SUBJECT ADDED ENTRY--TOPICAL TERM |
Topical term or geographic name entry element |
Paclitaxel |
9 (RLIN) |
970 |
650 ## - SUBJECT ADDED ENTRY--TOPICAL TERM |
Topical term or geographic name entry element |
Prosthesis Design |
9 (RLIN) |
81 |
650 ## - SUBJECT ADDED ENTRY--TOPICAL TERM |
Topical term or geographic name entry element |
Retrospective Studies |
9 (RLIN) |
46 |
650 ## - SUBJECT ADDED ENTRY--TOPICAL TERM |
Topical term or geographic name entry element |
Sirolimus/pd [Pharmacology] |
9 (RLIN) |
971 |
650 ## - SUBJECT ADDED ENTRY--TOPICAL TERM |
Topical term or geographic name entry element |
Treatment Outcome |
9 (RLIN) |
18 |
651 ## - SUBJECT ADDED ENTRY--GEOGRAPHIC NAME |
Institution |
MedStar Heart & Vascular Institute |
657 ## - INDEX TERM--FUNCTION |
Medline publication type |
Comparative Study |
657 ## - INDEX TERM--FUNCTION |
Medline publication type |
Journal Article |
657 ## - INDEX TERM--FUNCTION |
Medline publication type |
Randomized Controlled Trial |
657 ## - INDEX TERM--FUNCTION |
Medline publication type |
Research Support, Non-U.S. Gov't |
700 ## - ADDED ENTRY--PERSONAL NAME |
Local Authors |
Barbash, Israel M |
9 (RLIN) |
965 |
700 ## - ADDED ENTRY--PERSONAL NAME |
Local Authors |
Ben-Dor, Itsik |
9 (RLIN) |
22 |
700 ## - ADDED ENTRY--PERSONAL NAME |
Local Authors |
Dvir, Danny |
9 (RLIN) |
23 |
700 ## - ADDED ENTRY--PERSONAL NAME |
Local Authors |
Kent, Kenneth M |
9 (RLIN) |
135 |
700 ## - ADDED ENTRY--PERSONAL NAME |
Local Authors |
Maluenda, Gabriel |
9 (RLIN) |
286 |
700 ## - ADDED ENTRY--PERSONAL NAME |
Local Authors |
Pichard, Augusto D |
9 (RLIN) |
27 |
700 ## - ADDED ENTRY--PERSONAL NAME |
Local Authors |
Satler, Lowell F |
9 (RLIN) |
29 |
700 ## - ADDED ENTRY--PERSONAL NAME |
Local Authors |
Suddath, William O |
9 (RLIN) |
139 |
700 ## - ADDED ENTRY--PERSONAL NAME |
Local Authors |
Torguson, Rebecca |
9 (RLIN) |
140 |
700 ## - ADDED ENTRY--PERSONAL NAME |
Local Authors |
Waksman, Ron |
9 (RLIN) |
30 |
700 ## - ADDED ENTRY--PERSONAL NAME |
Local Authors |
Xue, Zhenyi |
9 (RLIN) |
141 |
790 ## - Authors |
All authors |
Barbash IM, Ben-Dor I, Dvir D, Kent KM, Maluenda G, Pichard AD, Satler LF, Suddath WO, Torguson R, Waksman R, Xue Z |
856 ## - ELECTRONIC LOCATION AND ACCESS |
DOI |
<a href="http://dx.doi.org/10.1016/j.amjcard.2011.12.019">http://dx.doi.org/10.1016/j.amjcard.2011.12.019</a> |
Public note |
http://dx.doi.org/10.1016/j.amjcard.2011.12.019 |
942 ## - ADDED ENTRY ELEMENTS (KOHA) |
Koha item type |
Journal Article |
Source of classification or shelving scheme |
Other/Generic Classification Scheme |
Item type description |
Article |